Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.

Gellad WF, Zhao X, Thorpe CT, Thorpe JM, Sileanu FE, Cashy JP, Mor M, Hale JA, Radomski T, Hausmann LR, Fine MJ, Good CB.

Subst Abus. 2017 Jan-Mar;38(1):22-25. doi: 10.1080/08897077.2016.1267071. Epub 2016 Dec 7.

2.

Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Weinstein ZM, Cheng DM, Quinn E, Hui D, Kim H, Gryczynski G, Samet JH.

Drug Alcohol Depend. 2017 Jan 1;170:9-16. doi: 10.1016/j.drugalcdep.2016.10.039. Epub 2016 Nov 5.

3.

Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR.

Drug Alcohol Depend. 2016 May 1;162:190-8. doi: 10.1016/j.drugalcdep.2016.03.005. Epub 2016 Mar 14.

4.

Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

Tucker D, Hayashi K, Milloy MJ, Nolan S, Dong H, Kerr T, Wood E.

Addict Behav. 2016 Jan;52:103-7. doi: 10.1016/j.addbeh.2015.10.002. Epub 2015 Oct 9.

5.

Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Jones JD, Atchison JJ, Madera G, Metz VE, Comer SD.

Drug Alcohol Depend. 2015 Aug 1;153:201-6. doi: 10.1016/j.drugalcdep.2015.05.021. Epub 2015 May 27.

6.

Buprenorphine treatment for narcotic addiction: not without risks.

Sansone RA, Sansone LA.

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):32-6.

7.

A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Lofwall MR, Walsh SL.

J Addict Med. 2014 Sep-Oct;8(5):315-26. doi: 10.1097/ADM.0000000000000045. Review.

8.

Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ.

Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. Epub 2013 May 18.

9.

Polydrug abuse: a review of opioid and benzodiazepine combination use.

Jones JD, Mogali S, Comer SD.

Drug Alcohol Depend. 2012 Sep 1;125(1-2):8-18. doi: 10.1016/j.drugalcdep.2012.07.004. Epub 2012 Aug 2. Review.

10.

Update on the clinical use of buprenorphine: in opioid-related disorders.

Ducharme S, Fraser R, Gill K.

Can Fam Physician. 2012 Jan;58(1):37-41. Review.

11.

Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Tetrault JM, Fiellin DA.

Drugs. 2012 Jan 22;72(2):217-28. doi: 10.2165/11597520-000000000-00000. Review.

12.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND.

J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.

13.

Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.

Fishman MJ, Wu LT, Woody GE.

Am J Psychiatry. 2011 Jul;168(7):675-9. doi: 10.1176/appi.ajp.2010.10060879. No abstract available.

14.

Factors associated with complicated buprenorphine inductions.

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO.

J Subst Abuse Treat. 2010 Jul;39(1):51-7. doi: 10.1016/j.jsat.2010.04.001.

15.

Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.

Unger A, Jung E, Winklbaur B, Fischer G.

J Addict Dis. 2010 Apr;29(2):217-30. doi: 10.1080/10550881003684814.

16.

Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

McCance-Katz EF, Sullivan LE, Nallani S.

Am J Addict. 2010 Jan-Feb;19(1):4-16. doi: 10.1111/j.1521-0391.2009.00005.x. Review.

17.

Practical considerations for the clinical use of buprenorphine.

Jones HE.

Sci Pract Perspect. 2004 Aug;2(2):4-20. Review.

18.

Treatment of opioid-dependent pregnant women: clinical and research issues.

Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, Stine SM, O'Grady KE, Arria AM, Fischer G.

J Subst Abuse Treat. 2008 Oct;35(3):245-59. doi: 10.1016/j.jsat.2007.10.007. Epub 2008 Jan 14. Review.

19.

Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate.

Avachat A, Kotwal V.

AAPS PharmSciTech. 2007 Oct 19;8(4):E88. doi: 10.1208/pt0804088.

20.

Supplemental Content

Support Center